While Janssen's Tremfya and Sun Pharmaceutical's Ilumya are Enjoying Continued Uptake, AbbVie's Skyrizi (Risankizumab) is Shaping up to be a Major Disruptor to the US Psoriasis Market if Approved

Tuesday, March 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Janssen's ECLIPSE clinical trial data demonstrating sustained response of Tremfya in comparison to Novartis' Cosentyx will have an impact on US dermatologists' prescribing behavior, according to a recent study by Spherix Global Insights



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store